Navigation Links
BioMarin to Present at the Collins Stewart Growth Conference
Date:7/1/2008

NOVATO, Calif., July 1 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced today that Emil Kakkis, M.D., Ph.D., Chief Medical Officer of BioMarin, will present a company update at the Collins Stewart Growth Conference in New York City on Wednesday, July 9, 2008 at 9:30 a.m. ET.

Interested parties may access a live audio webcast of the presentation via the investor section of the BioMarin website, http://www.BMRN.com. A replay of the presentation will be archived on the site for at least one week following the presentation.

About BioMarin

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises three approved products and multiple clinical and preclinical product candidates. Approved products include Naglazyme(R) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme(R) (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; and Kuvan(R) (sapropterin dihydrochloride) Tablets, a product for the treatment of phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany. Other product candidates include 6R-BH4 for cardiovascular indications, which is currently in Phase 2 clinical development for the treatment of peripheral arterial disease and sickle cell disease, and PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase 1 clinical development for the treatment of PKU. For additional information, please visit http://www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.

BioMarin(R), and Naglazyme(R) and Kuvan(R) are registered trademarks of BioMarin Pharmaceutical Inc.
Aldurazyme(R) is a registered trademark of BioMarin/Genzyme LLC.

Contacts:

Investors Media

Eugenia Shen Susan Berg

BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical Inc.

(415) 506-6570 (415) 506-6594


'/>"/>
SOURCE BioMarin Pharmaceutical Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. SciQuest Announces Newest Life Sciences Customer; BioMarin Pharmaceutical Drives Spending Effectiveness with Automated, Intuitive Procurement
2. BioMarin Announces Program for ERT for Treatment of MPS IVA - Morquio A Syndrome
3. BioMarin to Host Research and Development Day June 5th
4. BioMarin to Present at the Bank of America Healthcare Conference
5. BioMarin Announces First Quarter 2008 Financial Results
6. BioMarin to Present at the Morgan Stanley Healthcare Conference
7. BioMarin to Host First Quarter 2008 Financial Results Conference Call and Webcast on Tuesday, April 29 at 5:00 p.m. ET (23:00 CET)
8. BioMarin Announces Fourth Quarter and Full Year 2007 Financial Results
9. BioMarin to Present at the Merrill Lynch 2008 Global Healthcare Conference
10. BioMarin Appoints Dr. Gordon Vehar, Vice President of Research
11. BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... NEW YORK , May 26, 2016 ... industry, investors see value in this space. Today,s pre-market research ... Healthcare equities: Radius Health Inc. (NASDAQ: RDUS ), ... (NASDAQ: ARWR ), and Five Prime Therapeutics Inc. ... these stock technical briefings at: http://www.activewallst.com/ ...
(Date:5/26/2016)... ... May 26, 2016 , ... Kinder Scientific (KinderScientific.com), a ... that position the Company for the future. Kinder Scientific announces restructured ownership ... has been appointed Chairman of the Board, Curtis D. Kinghorn has been appointed ...
(Date:5/25/2016)... ... May 25, 2016 , ... Lajollacooks4u has become a rising hotspot for ... one of its top attractions. Fortune 500 companies, such as Illumina, Hewlett-Packard, Qualcomm ... and intimate team-building experience. , Each event kicks off with an olive oil and ...
(Date:5/25/2016)... ... May 25, 2016 , ... The Ankle ... plating options designed to address fractures of the distal tibia and fibula. This ... Acumed Ankle Plating System 3 is composed of seven plate families that span ...
Breaking Biology Technology:
(Date:5/3/2016)... Lithuania , May 3, 2016  Neurotechnology, ... released the MegaMatcher Automated Biometric Identification System ... of large-scale multi-biometric projects. MegaMatcher ABIS can process ... accuracy using any combination of fingerprint, face or ... MegaMatcher SDK and MegaMatcher Accelerator ...
(Date:4/28/2016)... -- First quarter 2016:   , Revenues ... first quarter of 2015 The gross margin was 49% ... and the operating margin was 40% (-13) Earnings per ... from operations was SEK 249.9 M (21.2) , Outlook ... 7,000-8,500 M. The operating margin for 2016 is estimated ...
(Date:4/26/2016)... Research and Markets has announced ... 2016-2020"  report to their offering.  , ,     (Logo: ... analysts forecast the global multimodal biometrics market to ... period 2016-2020.  Multimodal biometrics is being ... the healthcare, BFSI, transportation, automotive, and government for ...
Breaking Biology News(10 mins):